Abstract Number: 1573 • 2019 ACR/ARP Annual Meeting
Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort
Background/Purpose: The prevalence of atherosclerotic vascular events (AVE) in published literature of an inception cohort with SLE is 10%. We aimed to investigate the accrual…Abstract Number: 517 • 2018 ACR/ARHP Annual Meeting
Effects of Statin-Treatment on Coronary Plaques in Patients with Inflammatory Joint Diseases
Effects of Statin-treatment on Coronary Plaques in Patients with Inflammatory Joint DiseasesBackground/Purpose: Statins have an established preventive effect on coronary artery disease in the general…Abstract Number: 1071 • 2018 ACR/ARHP Annual Meeting
Protective Role of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Rs2495477 Polymorphism in Patients with Rheumatoid Arthritis
Background/Purpose: RA is associated with the development of cardiovascular (CV) disease and subclinical atherosclerosis, which leads to an increased risk of CV mortality in RA…Abstract Number: 1155 • 2018 ACR/ARHP Annual Meeting
A Collaborative Cardio-Rheumatology Clinic for Primary Prevention of Cardiovascular Diseases – a Descriptive Study
Background/Purpose: Patients with inflammatory arthritis are at increased risk for atherosclerotic cardiovascular (CV) disease. This has been under-recognized in clinical practice. Additionally, the current risk…Abstract Number: 1290 • 2018 ACR/ARHP Annual Meeting
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout studyBackground/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas…Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…Abstract Number: 1590 • 2018 ACR/ARHP Annual Meeting
Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease
Background/Purpose: Metabolomic profiling of patients with psoriatic disease (PsD) offers unparalleled opportunity to unravel the molecular and clinical interactions linking PsD with cardiovascular (CV) risk.…Abstract Number: 1608 • 2018 ACR/ARHP Annual Meeting
The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
Background/Purpose: Patients with psoriatic disease (PsD) are at a high risk of developing cardiovascular events (CVE). The performance of clinical algorithms for cardiovascular risk stratification,…Abstract Number: 1650 • 2018 ACR/ARHP Annual Meeting
Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis
Background/Purpose: There is evidence that shows an increased cardiovascular risk in patients with Axial Spondyloarthritis (axSpA). Ultrasonography (US) is a simple imaging tool used to…Abstract Number: 1848 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is one of the more common chronic diseases of childhood that often persists into adulthood and can result in significant…Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…Abstract Number: 68 • 2018 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Identifies rs116199914 As an Intergenic Variant Associated with Carotid Intima-Media Thickness in Spanish Patients with Rheumatoid Arthritis
Background/Purpose: Cardiovascular (CV) disease is the most common cause of morbidity and mortality in patients with rheumatoid arthritis (RA) [1, 2]. Traditional CV risk factors…Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…Abstract Number: 497 • 2018 ACR/ARHP Annual Meeting
Increased Concentration of Large Very Low Density Lipoprotein Particles Associates with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a marked increase in cardiovascular (CV) morbidity and mortality compared to the general population. Conventional lipid profiles are…Abstract Number: 2827 • 2018 ACR/ARHP Annual Meeting
Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?
Background/Purpose: Systemic inflammation contributes to the excess risk of cardiovascular disease (CVD) in PsA. We had demonstrated that achieving sustained minimal disease activity (sMDA) was…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »